NPM1 and acute myeloid leukemia: Additionally, the CDK6 inhibitor abemaciclib synergizes with SNDX-5613 and KO-539 in MLLr and NPM1 mutant AML cell lines [189,191], with the combination resulting in a greater reduction in cell viability compared to menin inhibition alone [189].